Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jul;158(3):369-378.
doi: 10.1007/s11060-022-04024-5. Epub 2022 May 14.

Adult diffuse midline gliomas H3 K27-altered: review of a redefined entity

Carlos Axel López-Pérez  1 , Xochitl Franco-Mojica  1 , Ricardo Villanueva-Gaona  1 , Alexandra Díaz-Alba  1   2 , Marco Antonio Rodríguez-Florido  3 , Victor Garcia Navarro  4   5
Affiliations
Review

Adult diffuse midline gliomas H3 K27-altered: review of a redefined entity

Carlos Axel López-Pérez et al. J Neurooncol. 2022 Jul.

Abstract

Introduction: Diffuse midline glioma (DMG) H3 K27-altered is a type of high-grade gliomas first recognized as a new entity in the 2016 World Health Organization Classification of Central Nervous System (CNS) Tumors as DMG H3 K27M-mutant, recently renamed in the new 2021 WHO classification. The aim of this review is to describe the characteristics of diffuse midline gliomas H3 K27-altered in the adult population.

Methods: We performed a review of the current literature regarding the genetic, clinical, imaging characteristics and management of diffuse midline gliomas H3 K27-altered in adult patients.

Results: The 2021 WHO classification now designates the previously recognized DMG H3K27M-mutant as DMG H3 K27-altered, recognizing the alternative mechanisms by which the pathogenic pathway can be altered. Thus, the diagnostic criteria for this entity consist of diffuse growth pattern, midline anatomic location, and H3 K27-specific neuroglial mutations. DMGs' characteristic midline location makes them difficult to surgically resect and biopsy, carrying high mortality and morbidity rates, with median survival ranging from 9 to 12 months in adult patients.

Conclusion: The diagnosis of DMGs H3 K27-altered in adult patients should be considered upon neurological symptoms associated with an infiltrative midline brain tumor detected on imaging. Future studies are necessary to continue refining their characteristics in this age group.

Keywords: Diffuse midline gliomas; H3 K27-altered; H3 K27M-mutant; Neuro-oncology.

PubMed Disclaimer

References

    1. Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK et al (2016) The 2016 world health organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131:803–820. https://doi.org/10.1007/s00401-016-1545-1 - DOI - PubMed
    1. Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D et al (2021) The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol 23:1231–1251. https://doi.org/10.1093/neuonc/noab106 - DOI - PubMed - PMC
    1. Schreck KC, Ranjan S, Skorupan N, Bettegowda C, Eberhart CG, Ames HM et al (2019) Incidence and clinicopathologic features of H3 K27M mutations in adults with radiographically-determined midline gliomas. J Neurooncol. https://doi.org/10.1007/s11060-019-03134-x - DOI - PubMed - PMC
    1. Yoon HI, Wee CW, Kim YZ, Seo Y, Im JH, Dho Y-S et al (2021) The Korean society for neuro-oncology (KSNO) guideline for adult diffuse midline Glioma: version 2021.1. Brain Tumor Res Treat 9:1 - DOI
    1. Schulte JD, Buerki RA, Lapointe S, Molinaro AM, Zhang Y, Villanueva-Meyer JE et al (2020) Clinical, radiologic, and genetic characteristics of histone H3 K27M-mutant diffuse midline gliomas in adults. Neuro-Oncol Adv. https://doi.org/10.1093/noajnl/vdaa142 - DOI

LinkOut - more resources